Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis

Not Applicable

Completed

Conditions: Psoriasis

Interventions: Drug: Calcipotriol Betamethasone ointment and Calcipotriol ointment
Drug: Calcipotriol Betamethasone ointment and Urea Cream
Drug: Calcipotriol Betamethasone ointment

First Posted Date: 2014-07-15

Last Posted Date: 2014-07-15

Lead Sponsor: Xijing Hospital

Target Recruit Count: 230

Registration Number: NCT02191007

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Phase 3

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Gel vehicle
Drug: LEO 90100 aerosol foam
Drug: Calcipotriol BDP gel
Drug: Aerosol foam vehicle

First Posted Date: 2014-05-07

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 504

Registration Number: NCT02132936

Locations: 🇫🇷
Service de Dermatologie, Hôspital Larrey, Toulouse, France

Actinic Keratosis Study

Early Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: 5-fluorouracil 5% cream
Drug: Calcipotriol 0.005% ointment
Drug: Vaseline

First Posted Date: 2013-12-24

Last Posted Date: 2016-05-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 132

Registration Number: NCT02019355

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris

Phase 1

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Calcipotriol plus BDP gel in different doses

First Posted Date: 2013-04-23

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 24

Registration Number: NCT01837576

Locations: 🇫🇷
Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, Nice Cedex 3, France

Nicotinamide in the Treatment of Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Calcipotriol plus Nicotinamide
Drug: Calcipotriol

First Posted Date: 2013-01-08

Last Posted Date: 2013-01-08

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 66

Registration Number: NCT01763424

Locations: 🇮🇷
Skin Diseases and Leishmaniasis Research Center, Isfahan, Iran, Islamic Republic of

A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Taclonex Topical Suspension

First Posted Date: 2013-01-04

Last Posted Date: 2016-09-21

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 8

Registration Number: NCT01761019

Locations: 🇺🇸
UPMC Department of Dermatology, Falk Clinic, Pittsburgh, Pennsylvania, United States

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: vehicle foam
Drug: calcipotriene + clobetasol propionate
Drug: calcipotriene

First Posted Date: 2012-12-07

Last Posted Date: 2016-11-17

Lead Sponsor: Leon Kircik, M.D.

Target Recruit Count: 63

Registration Number: NCT01745133

Locations: 🇺🇸
DermResearch, PLLC, Louisville, Kentucky, United States

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Taclonex

First Posted Date: 2012-10-15

Last Posted Date: 2018-09-10

Lead Sponsor: Wake Forest University

Target Recruit Count: 20

Registration Number: NCT01707043

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: Calcipotriene

First Posted Date: 2012-09-27

Last Posted Date: 2019-05-07

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 66

Registration Number: NCT01694433

Locations: 🇺🇸
UCLA Dermatology, Los Angeles, California, United States

SHP-141C in Plaque Type Psoriasis

Phase 1

Completed

Conditions: Plaque Type Psoriasis

Interventions: Drug: SHP-141C
Drug: Placebo to SHP-141C
Drug: Betamethasone Valerate
Drug: Calcipotriol

First Posted Date: 2012-07-20

Last Posted Date: 2014-07-11

Lead Sponsor: TetraLogic Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01646567

Locations: 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy